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Authors’ reply 
Martin McKee, Anna Gilmore, and Mats Lambe identify some important reasons for caution in 
promoting snus. We agree that controlled trials are needed to confirm the Swedish observational 
studies that suggest that snus is an effective quitting aid,1 but we are not as concerned that the 
dual use of snus and cigarettes will deter smokers from quitting. First, nicotine replacement 
therapy is already used in this way, and even promoted by some health professionals for 
reducing smoking quantity rather than quitting.2 Second, in Sweden such dual use usually leads 
to smoking cessation.1   
We agree that the tobacco industry should be prevented from promoting dual use of snus by 
continuing the total ban on all tobacco advertising that applies in Australia. Before existing bans 
on low nitrosamine oral tobacco products are relaxed, we need more research into how attractive 
current smokers find snus as an alter native to smoking and how likely smokers are to engage in 
long-term dual use with cigarettes.  
McKee and Gilmore suggest that our model underestimated the risk of death from 
cardiovascular disease caused by snus because one study reported a 40% increase in 
cardiovascular death in snus users compared with nonsmokers.3 We reran the simulation, with 
snus use assigned the same risk of death from cardiovascular disease as smoking. Large health 
gains were still seen if smokers switched to snus (table). Even assuming a greater effect of snus 
on cardiovascular disease, the difference in health-adjusted life expectancy between lifelong non-
tobacco users and snus users who never smoked ranged from 0·3 to 0·6 years, whereas that 
between quitting tobacco use and switching to snus ranged from 0·1 to 0·4 years, depending on 
the age at which the smoker quit or switched to snus.  
We wholeheartedly agree that the regulation of nicotine products should be proportional to the 
harm that they cause. In Australia, pharmaceutical nicotine replacement therapy that is much like 
cigarettes is available in supermarkets, but snus is completely banned from sale. Yet new 
tobacco products can be introduced to the market so long as they are smoked. Philip Morris has 
recently received a green light from the Australian government to sell a potential reduced 
exposure cigarette which it claims reduces second-hand smoke emissions by 90%.4 A 
continuation of bans on snus means that smokers interested in reduced-harm products can only 
use putatively reduced-risk products that have at best uncertain health risks and probably higher 
ones than those of snus. 
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